Compare Novartis AG (NVS) vs Shopify Inc. (SHOP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Shopify Inc. — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Shopify Inc. trades at $165.34 (market cap $211.73B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays a 3.31% dividend while Shopify Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Shopify Inc. for 78 Days on average.
| NVS | SHOP | |
|---|---|---|
Market Cap | $268.57B | $211.73B |
Volume | 1,532,573 | 7,146,651 |
Sector | Health | Technology |
52-Week High | $168.62 | $179.01 |
52-Week Low | $121.80 | $95.40 |
Typical Hold Time | 82 Days | 78 Days |
Enterprise Value | $309.89B | $206.96B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Shopify (SHOP) trades at $165.94, up 0.88% today, showing strong momentum near analyst consensus targets. The stock maintains a bullish technical outlook with solid fundamental growth - revenue increased from $5.6B in 2022 to $11.6B in 2025 while achieving profitability. Recent earnings show mixed results with Q4 2025 missing estimates but Q1 and Q2 2026 beating expectations. The company continues to innovate with AI-powered commerce tools and expanding merchant solutions.
Shopify presents growth potential through e-commerce leadership and AI integration, though elevated valuation metrics (P/E 112, P/S 16) warrant caution. Key risks include competitive pressures from Amazon and valuation sensitivity to growth sustainability. Analyst consensus remains bullish with 67% buy ratings and $168.63 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
